Skip to main content
. 2014 Jan;94(1):1–34. doi: 10.1152/physrev.00017.2013

FIGURE 4.

FIGURE 4.

Diseases in which activators of ALDH2 may be beneficial. See text for full discussion. Red highlights diseases where the evidence for ALDH2 role came from preclinical proof-of-concept studies. Blue highlights diseases where ALDH2 role was supported by clinical observations. Black highlights diseases where evidence from both preclinical studies and from human epidemiological or pathohistological studies supports a role for ALDH2.